Ocugen’s Strategic Pivot: Betting Everything on Vision Therapies

Biotechnology firm Ocugen has announced a fundamental restructuring of its operations, marking a decisive shift in corporate strategy. The company will completely spin off its orthopedic business unit to concentrate exclusively on developing ophthalmology treatments. This move represents a significant gamble on the future direction of the company and has immediate implications for its shareholders.

The restructuring centers on merging Ocugen’s subsidiary, OrthoCellix, with Carisma Therapeutics. This transaction will establish an entirely new independent company named OrthoCellix, Inc., which is scheduled to launch on the Nasdaq exchange under the ticker symbol “OCLX” during the second half of 2025. The primary focus of this new entity will be the NeoCart® technology platform, an innovative implant designed for knee cartilage repair.

A... Read more...